Journal of cardiovascular electrophysiology
-
J. Cardiovasc. Electrophysiol. · Sep 2003
Randomized Controlled Trial Clinical TrialAnalysis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial.
The implantable cardioverter defibrillator (ICD) is commonly used to treat patients with documented sustained ventricular tachycardia (VT) or ventricular fibrillation (VF). Arrhythmia recurrence rates in these patients are high, but which patients will receive a therapy and the forms of arrhythmia recurrence (VT or VF) are poorly understood. ⋯ Delivery of ICD therapy in AVID patients was common, primarily due to VT. Inappropriate ICD therapy occurred frequently. Use of ICD therapy as a surrogate endpoint for death in clinical trials should be avoided.
-
J. Cardiovasc. Electrophysiol. · Aug 2003
Randomized Controlled Trial Clinical TrialBiphasic versus monophasic cardioversion in shock-resistant atrial fibrillation:.
Biphasic versus Monophasic Cardioversion. ⋯ An ascending sequence of 150-, 200-, and 360-J transthoracic biphasic cardioversion shocks are successful more often than a single 360-J monophasic shock. Thus, biphasic shocks should be the recommended configuration of choice for all cardioversions.
-
J. Cardiovasc. Electrophysiol. · Jul 2001
Randomized Controlled Trial Comparative Study Clinical TrialVERDICT: the Verapamil versus Digoxin Cardioversion Trial: A randomized study on the role of calcium lowering for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation.
Many relapses of atrial fibrillation (AF) occur, especially during the first week(s) after electrical cardioversion (ECV). The aim of the present study was to compare in a randomized design the efficacy of verapamil (intracellular calcium lowering) versus digoxin (calcium increasing) for maintenance of sinus rhythm after ECV. ⋯ Stand-alone intracellular calcium lowering by verapamil around ECV does not enhance cardioversion outcome.